Retatrutide in 2026: what the phase 3 numbers mean
Why TRIUMPH-1 reports both 25.0% and 28.3% weight loss, what its safety findings show, and how those results differ from FDA approval.
Follow a thread
Clinical trials
3 stories found Clear filters ↗
The archive
3 storiesClinical trials
GLP-1 and GIP: reading the semaglutide–tirzepatide comparison
A receptor count cannot rank a medicine. Current US labels and the SURMOUNT-5 trial show why product, population and outcome must stay attached to every comparison.
How to read a peptide trial without losing the plot
A trial number begins an investigation. Use real BPC-157 and SELECT records to separate registration, results, absolute benefits, observed harms and a specific FDA approval.